



ASX ANNOUNCEMENT

15 September 2021

NOTICE OF DATE OF FORTHCOMING AGM & OTHER RELEVANT DATES

15 September 2021 – Pursuant to ASX Listing Rule 3.13.1, Cann Group Limited (ASX:CAN) (the **Company**) is pleased to advise the following details in relation to the Company's forthcoming Annual General Meeting (**AGM**), which will be held by way of a virtual meeting:

- **Date and time for AGM:** Wednesday, 10 November 2021 at 2.00pm (Melbourne time)
- **Date of Notice of Meeting dispatch:** Friday, 8 October 2021
- **Last date for receipt of nominations as a director:** Wednesday, 22 September 2021

Further details in relation to the AGM, including items of business to be voted upon by shareholders, and instructions on how shareholders may attend and vote at the meeting, will be provided in the Notice of Meeting.

The Company's Appendix 4E, together with the FY21 Audited Financial Report, which includes the Remuneration Report, were lodged with the ASX on 23 August 2021. They can be accessed and downloaded from the Company's website [here](#). The Company's Annual Report is expected to be released on or about 23 September 2021 and will also be accessible on the Company's website. Once that report is released, shareholders can also obtain a hard copy by emailing a request to the Company at communications@canngrouplimited.com.

The Company looks forward to shareholders participating at this year's AGM.

Authorised for release by Geraldine Farrell, Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
clive.fanning@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouplimited.com | www.satipharm.com